Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:41:02.837Z.
Calculation as of: 2026-10-06T15:41:02.837Z.
Quote observation: 2026-10-06T15:38:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b47096c20191003074eea3dc75a1498d2bed5743fa2797f84e024bc92f81a74c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$11.95M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.44M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.30M
Price/OCF Ratio
N/A
TTM Avg
6.96
3Y Avg
6.96
5Y Avg
6.96
Market Cap
$11.21M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biofrontera Inc. (BFRI) | $11.82M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.95M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.12M | N/A | 9.81 | 9.81 | 9.81 |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.44M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.30M | N/A | 6.96 | 6.96 | 6.96 |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.21M | N/A | N/A | N/A | N/A |
| Pluri Inc. (PLUR)vs › | $11.11M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.57M | N/A | 3.83 | 3.83 | 3.83 |
| BioVie Inc. (BIVI)vs › | $11.09M | N/A | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.93M | N/A | 5.31 | 5.31 | 5.31 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
